Neisseria meningitidis strains from patients with invasive meningococcal disease differ in stimulation of cytokine production

Folia Microbiologica

Volumn 52, Issue 5, 2007, Pages 525-528

  Holub, M ^a   Scheinostova M ^a   Dzupova O ^a   Fiserova A ^a   Beran, O ^a   Kalmusova J ^b   Musilek M ^b   Krizova P ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; LIPID LINKED OLIGOSACCHARIDES; LIPID-LINKED OLIGOSACCHARIDES; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CLASSIFICATION; EPIDEMIC MENINGITIS; FEMALE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PATHOGENICITY; VIRULENCE;

ADULT; CYTOKINES; ENDOTOXINS; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MALE; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; VIRULENCE;

NEISSERIA MENINGITIDIS;

EID: 37649005206     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02932114     Document Type: Article

References (12)

1. CAVAILLON J.M.: Proinflammatory and anti-inflammatory cytokines as mediators of Gram-negative sepsis, pp. 33-37 in M. Kotb, T. Calandra (Eds): Cytokines and Chemokines in Infectious Diseases Handbook. Humana Press, Totowa (USA) 2003.
2. CLEMENTIEN L.V., GROOT R., HAZELZET J.A.: Bench-to-bedside review: genetic influences on meningococcal disease. Crit.Care 6, 60-65 (2001).
3. KAHLER C.M., STEPHENS D.S.: Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit.Rev.Microbiol. 24, 281-334 (1989).
4. KŘÍZOVá P.: The 2001 serological survey in the Czech Republic - invasive meningococcal disease. Central Eur.J.Public Haelth 11 (Suppl.), S62-S67 (2003).
5. KVALSVIG A.J., UNSWORTH D.J.: The immunopathogenesis of meningococcal disease. Clin.Pathol. 56, 417-422 (2003).
6. EHNER P.J., DAVIES K.A., WALPORT M.J., COPE A.P., WURZNER R., ORREN A., MORGAN B.P., COHEN J.: Meningococcal septicemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet 340, 1379-1381 (1992).
7. NASSIF X., MATHISON J.C., WOLFSON E., KOZIOL J.A., ULEVITCH R.J., So M.: Tumor necrosis factor α antibody protects against lethal meningococcemia. Mol.Microbiol. 6, 591-597 (1992).
8. PLANT L., SUNDQVIST J., ZUGHAIER S., LOVKVIST L., STEPHENS D.S., JONSSON A.B.: Lipooligosaccharide structure contributes to multiple steps in the virulence of Neisseria meningitidis. Infect.Immun. 74, 1360-1367 (2006).
9. PRINS J.M., LAUW F.N., DERKX B.H., SPEELMAN P., KUUPER E.J., DANKERT J., VAN DEVENTER S.J.: Endotoxin release and cytokine production in acute and chronic meningococcaemia. Clin.Exp.Immunol. 114, 215-219 (1998).
10. ROSENSTEIN N.B., PERKINS B.A., STEPHENS D.S., POPOVIC T., HUGHES J.M.: Meningococcal disease. N.Engl.J.Med. 344, 1378-1388 (2001).
11. SCHLESINOER M., KAYHTY H., LEVY R., BIBI C., MEYDAN N., LEVY J.: Phagocytic killing and antibody response during the first year after tetravalent meningococcal vaccine in complement-deficient and in normal individuals. J.Clin.Immunol. 20, 46-53 (2000).
12. VAN DEUREN M., BRANDTZAEG P., VAN DER MEER J.W.M.: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin.Microbiol.Rev. 13, 144-166 (2000).